In this article, Subbarayan et al. evaluate how the ACE2 receptor, used by SARS-CoV-2 to enter cells, affects immune responses in cancer. The authors find that tumor cells with high levels of ACE2 show increased activation of immune-related genes and molecules. These changes may influence how well cancer patients respond to immunotherapy, especially when infected with COVID-19. The study suggests that targeting the ACE2-related immune pathway could help reduce COVID-19 severity in patients with cancer.
